Skip to content
Bored Studies
Recruiting

Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)

Innova Vascular, Inc. · NCT06041594

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–85 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Not applicable
Target enrollment
107
US sites recruiting
13
Study start
August 19, 2024
Record last updated
July 17, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This is a prospective, multi-center, pivotal study to demonstrate the safety and effectiveness of the Laguna Thrombectomy System for the treatment of pulmonary embolism. The Laguna Thrombectomy System is an investigational device which consists of the Laguna Clot Retriever™ System and the Malibu Aspiration Catheter™ System. These devices are manufactured by Innova Vascular, Inc.

Being studied: Laguna Thrombectomy System

Conditions: Pulmonary Embolism

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • ≥ 18 years of age; \< 85 years old
  • RV/LV ratio > 0.9 as determined by CTA
  • Systolic blood pressure > 90 mmHg
  • Heart rate ≤ 120
  • Patient is deemed eligible for procedure by the interventional investigator
  • CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery)
  • PE Symptom duration ≤ 14 days

Exclusion Criteria

  • Systolic pulmonary artery pressure > 70 mmHg on initial invasive hemodynamic assessments
  • Life expectancy of \< 90 days in the opinion of investigator at the time of enrollment
  • Subject pregnant or breast feeding
  • Current participation in another drug or medical device treatment study
  • In active chemotherapy or radiation treatment for a malignancy during the course of the study
  • Any intravascular administration of a fibrinolytic agent (such as Alteplase or Tenecteplase) within the last 30 days
  • Presence of recently placed (\<8 weeks) intracardiac devices (such as pacemaker leads) in the right ventricle or right atrium
  • History of prior PE within the past 90 days
  • FiO2 Requirement: > 40% (6 LPM) to keep oxygen saturation > 90%
  • Hematocrit: \< 28%
  • Platelets: \< 100,000/microliter
  • Serum Creatinine: > 2 mg/dL
  • International Normalized Ratio (INR): > 3
  • Major Trauma Injury Severity Score (ISS): > 15
  • Cardiovascular or pulmonary surgery within the last 7 days
  • Known bleeding diathesis or coagulation disorder that cannot be managed with anti-coagulation
  • History of known severe or chronic pulmonary arterial hypertension
  • History or chronic left heart disease with left ventricular ejection fraction \< 30%
  • History of underlying lung disease that is oxygen dependent
  • History of chest irradiation
  • Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
  • Any absolute contraindication to systemic or therapeutic dosage of heparin or anticoagulants
  • Imaging or other evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target location, predominantly chronic clot or non-clot embolus)
  • Known presence of clot in transit within right atrium or ventricle

Recruiting US locations

Study contacts (from the official record)

  • Sanjay Shrivastava, Ph.D. · 949-295-6040 · ss@innovavascular.com
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST) (NCT06041594) | Bored Studies